Why the study?
Does atorvastatin 10 mg daily improve baroreflex sensitivity in patients with type 2 diabetes and dyslipidaemia?
Does atorvastatin 10 mg daily improve baroreflex sensitivity in patients with type 2 diabetes and dyslipidaemia?
Low-dose atorvastatin improves baroreflex sensitivity in non-obese patients with type 2 diabetes and dyslipidemia over 1 year, suggesting cardiovascular benefits beyond lipid lowering.
Answers are grounded in this paper and cite their sources.
Atorvastatin was associated with improved baroreflex sensitivity in type 2 diabetes; hypothesis-generating and requires randomized confirmation before practice change.
In this prospective study, we examined the effect of atorvastatin treatment on baroreflex sensitivity (BRS) in subjects with type 2 diabetes. A total of 79 patients with type 2 diabetes with dyslipidaemia were recruited. A total of 46 subjects were enrolled to atorvastatin 10 mg daily and low-fat diet and 33 patients to low-fat diet only. BRS was assessed non-invasively using the sequence method at baseline, 3, 6 and 12 months. Treatment with atorvastatin increased BRS after 12 months (from 6.46 ± 2.79 ms/mmHg to 8.05 ± 4.28 ms/mmHg, p = 0.03), while no effect was seen with low-fat diet. Further sub-analysis according to obesity status showed that BRS increased significantly only in the non-obese group (p = 0.036). A low dose of atorvastatin increased BRS in non-obese subjects with type 2 diabetes and dyslipidaemia after 1-year treatment. This finding emphasizes the beneficial effect of atorvastatin on cardiovascular system, beyond the lipid-lowering effects.
No takes yet. Share an insight, caveat, or question.
Grigoropoulou et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: